Skip to main content
Caplight Logo









APEX Biologix

APEX Biologix

Private
Woods Cross, UtahHealthcare & Life Scienceshttps://apexbiologix.com/

Last Round

Debt

Apr 10, 2026

Momentum

Top 50%

of companies Caplight tracks

Company Overview

APEX Biologix is a medical device company that designs and manufactures regenerative medicine products, including autologous biologic systems for platelet-rich plasma, bone marrow concentrate, and protein concentrate.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotech Equipment, Biotechnology, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

regenerative medicineplatelet-rich plasmaPRPbone marrow concentrateBMCmedical devicespoint-of-carebiologicsautologous cellscentrifugeorthopedic suppliesaesthetic medicineclinical trainingorthobiologicsstem cell therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

APEX Biologix Comparables

Compare APEX Biologix with similar companies based on industry and business-model similarity.

APEX Biologix comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Celling Biosciences
93%
EmCyte Corporation
90%
Royal Biologics
89%

APEX Biologix Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
DebtApr 10, 2026
DebtOct 14, 2025
DebtJul 15, 2025
DebtMar 24, 2025
AcceleratorMar 28, 2022
Buyout/LBO
Apr 16, 2021

Key People

Founding team and executive leadership

Jim Rogers

Chief Executive Officer

Executive Team

APEX Biologix Investors

Notable investors and investment history

APEX Biologix investors
InvestorRounds
RevTek CapitalDebt

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 26, 2026

    Monthly visitors increased 51% MoM, from 3.3K to 5K.

  • Oct 13, 2025

    Grew 38% QoQ, from 50 to 69 employees.

APEX Biologix Filings

Explore SEC and related filing metadata, where available.

APEX Biologix filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about APEX Biologix's valuation, stock price, and market status.

Is APEX Biologix a public or private company?

APEX Biologix is a private company.

What is the current stock price of APEX Biologix?

APEX Biologix is a private company with no public stock price. Caplight tracks APEX Biologix's secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is APEX Biologix worth (valuation)?

Valuation information for APEX Biologix is not publicly available.

Can I buy APEX Biologix stock?

APEX Biologix shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was APEX Biologix's last funding round?

APEX Biologix's most recent funding round was Debt on April 10, 2026.

Who are the main investors in APEX Biologix?

Key investors in APEX Biologix include RevTek Capital.

Will APEX Biologix IPO soon?

No public IPO plans have been announced for APEX Biologix.

How can I track APEX Biologix secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor APEX Biologix's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersWoods Cross, Utah
Employee Range49
Year Founded2014
Last FundingApr 10, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?